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Open surgery of thoracic aorta is as-
sociated with relatively high mortality 
and morbidity. Stent graft treatment 
was introduced on the side of open 
surgery to reduce mortality and mor-
bidity associated with the treatment. 
Stent graft treatment has, however, 
some limitations, but intra-operative 
fenestration may be a way to make 
this treatment more available. This 
study also confirmed that endovascu-
lar treatment of a thoracic aortic aneu-
rysm is relatively safe, but a rigorous 
postoperative surveillance program is 
still compulsory. In connective tis-
sue disorders open surgery is still the 
mainstay of the treatment, but endo-
vascular option should be considered 
to reduce operative complications.
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ABSTRACT 
 
Thoracic aortic aneurysms and dissections can lead to devastating complications and 
eventually to premature death. A diseased segment of the aorta has traditionally been 
replaced with a surgical prosthesis. Open surgery is, unfortunately, associated with 
relatively high mortality and morbidity. Stent graft treatment was introduced on the side of 
open surgery 20 years ago, and there have been high hopes that mortality and morbidity 
could be lowered with this kind of mini-invasive procedure. Experiences have been 
promising, and patients tend to survive better after stent graft treatment, at least in the 
short term. However, the long-term durability of the first-generation stent grafts was not 
sufficient, which led to unnecessary reoperations and even ruptures of the treated 
segments. Stent design has been improved since, but the survival benefit of the stent graft–
treated patients seems to vanish in 5 years. To be successful, stent graft treatment must 
overcome some limitations: Stent grafts need adequate landing zones in both ends of the 
graft, and important side branches of the aorta cannot be covered without consequences. 
The latest in stent graft design is the fenestrated graft, which was developed to overcome 
these obstacles. These grafts are very expensive, however, and because they have to be 
tailored individually to each patient, cannot be used in acute situations. 
Intraoperative fenestration of the stent graft may be a way to make this treatment more 
available. Stent graft fabrics are quite difficult to traverse, though, and the dilatation of the 
fenestration is greatly facilitated when a cutting balloon is used. Nevertheless, the device to 
be used in the creation of fenestration needs some improvements. 
Endovascular treatment of a thoracic aortic aneurysm is relatively safe, at least in the 
elective setting. However, to reduce the risk of periprocedural and postoperative 
complications, multidisciplinary and detailed preoperative imaging-based planning is 
helpful. A rigorous postoperative surveillance program is still compulsory for early 
detection and prompt treatment of late type I or III endoleak and to reduce the risk of late 
ruptures. 
Marfan syndrome and especially Loeys–Dietz syndrome are debilitating connective 
tissue disorders, and these patients are very prone to developing vascular complications, 
particularly of the aorta. The nature of these diseases mandates aggressive treatment 
strategies and close surveillance programs. Open surgery remains the mainstay of the 
treatment, but endovascular options should be considered whenever possible to reduce 
operative complications. Endovascular treatment should be planned so that the landing 
zones lie within the previously treated aorta. 
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TIIVISTELMÄ:  
 
Rinta-aortan aneurysmat ja dissekaatiot ovat vakavia sairauksia, joiden akuuttien 
komplikaatioiden, kuten esimerkiksi aortan repeämän, seurauksena potilas sairastuu 
vakavasti ja pahimmillaan tilanne voi jopa johtaa ennenaikaiseen kuolemaan. Sairas aortan 
segmentti on perinteisesti korvattu avokirurgisessa leikkauksessa proteesilla. Kirurgiseen 
hoitoon valitettavasti liittyy varsin runsaasti komplikaatioita, minkä vuoksi on etsitty 
vähemmän potilasta rasittavia hoitomuotoja. Noin 20 vuotta sitten esiteltiin ensimmäisen 
kerran suonen sisäisesti tehtävä stettigraftihoito avokirurgian rinnalle ja sittemmin 
hoitomuoto on vallannut alaa varsin nopeassa tahdissa. Ainakin lyhyellä aikavälillä 
stenttigraftilla hoidetut potilaat selviytyvät paremmin kuin avokirurgisesti hoidetut 
potilaat, mutta varsinkin alkuvaiheessa stenttigraftien rakenne ei ollut riittävän luja, mikä 
johti tarpeettomiin uusintaoperaatioihin ja jopa aortan repeämiin. Stenttigraftien rakennetta 
on sittemmin parannettu, mutta siitä huolimatta ainakin toistaiseksi näyttää, että 
setenttigraftipotilaiden parempi ennuste kestää vain noin 5 vuotta operaatiosta. 
Stenttigraftihoito ei myöskään valttämättä sovellu kaikille potilaille, sillä proteesin 
molempiin päihin tarvitaan riittävän pitkät kiinnittymisalueet ja tärkeitä aortan haaroja ei 
voi peittää ilman vakavia komplikaatioita. Viimeisimmät kehitysaskeleet näiden ongelmien 
kiertämiseksi ovat ns. fenestroidut stenttigraftit. Nämä ovat kuitenkin huomattavan kalliita 
ja koska ne pitää suunnitella ja valmistaa jokaiselle potilaalle yksilöllisti, ne eivät sovellu 
akuutteihin tilanteisiin. 
Stenttigraftin asennuksen yhteydessä tehtävä fenestraatio voisi olla yksi tapa, jolla 
stenntigraftihoitoa voisi tarjota myös potilaille, joilla kiinnittymisalue jää lähellä sijaitsevan 
aortan sivuhaaran vuoksi muuten liian lyhyeksi. Stenttigraftien kangasmateriaali on tosin 
varsin vaikeasti läpäistävissä, joskin leikkaavan pallon avulla muodostettu fenestraatio on 
mahdollista laajentaa täyteen mittaansa.  Fenestraation luomisessa käytetty neulakatetri 
vaatii kuitenkin vielä jatkokehittelyä. 
Rinta-aortan aneurysmien hoito suonensisäisesti on ainakin elektiivisillä potilailla 
verrattaen turvallista. Operaation liittyvien komplikaatioiden minimoimiseksi edeltävä 
kuvantaminen on kuitenkin syytä suunnitella ja analysoida huolellisesti. Operaation 
jälkeinen seuranta on myös syytä toteuttaa säännöllisenä koko potilaan loppuelämän ajan, 
jotta mahdollisesti myöhemmin kehittyvät tyyppi I tai III lekaasit voitaisiin ajoissa hoitaa ja 
ehkäistä aneurysman puhkeaminen. 
Marfanin syndrooma ja erityisesti Loeys-Dietz  syndrooma ovat sidekudossairauksia, 
jotka johtavat hyvin nuorella iällä verisuonikomplikaatioihin erityisesti aortan alueella. 
Sairauksien luonne edellyttää varhaista puuttumista näihin verisuoniongelmiin ja potilaita 
on seurattava säännöllisesti. Avokirurgia on näiden potilaiden kohdalla yleensä 
pääasiallinen hoitomuoto, mutta suonensisäistä hoitoa kannattaa harkita avokirurgian 
ohessa vähentämään leikkauskomplikaatioita. Stenttigraftihoidot on näillä potilailla 
yleensä suunniteltava siten, että suonensisäisen proteesin kiinnittymisalueet tulevat aina 
aiemmin protetisoidun aortan alueella. 
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1 Introduction 
 
Diseases of the thoracic aorta can be divided into two main groups: congenital diseases, 
such as coarctation, and acquired diseases. The latter group can be further divided into 
three groups:  
1. Aneurysms 
2. Dissections, penetrating ulcers, and intramural hematoma (IMH) 
3. Traumatic ruptures 
Aneurysm formation can eventually lead to further enlargement of the aorta, which 
finally ruptures, and to the death of the patient, if left untreated. In dissection or IMH, the 
blood enters between the layers of the aortic wall, which can lead to the rupture of the 
aorta, pericardial tamponade, or aneurysm formation, which are associated with high 
mortality. Traumatic rupture of the aorta usually leads to death on location. Some patients, 
however, survive, and along with the treatment of other injuries, the ruptured aorta should 
also be repaired to prevent further complications. 
From the early 1950s, diseases of the thoracic aorta have been treated by replacing the 
diseased segment with a prosthesis. Surgery of the thoracic aorta is usually very 
demanding and associated with high morbidity and mortality. From the early 1990s, the 
endovascular technique has emerged on the side of surgical repair as less invasive. There 
have been hopes that an endovascular approach could reduce the rate of complications 
associated with the operative treatment. However, long-term durability of endovascular 
treatment is still lacking, and these patients need lifelong surveillance. Some unresolved 
issues in stent design also persist, such as how to handle the vitally important side branches 
in the aortic arch. 
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2 Review of the literature 
 
2.1 DISEASES OF THORACIC AORTA 
 
2.1.1 Etiology and pathophysiology 
The wall of the aorta is composed of three layers: intima, media, and adventitia. The intima 
is a single layer of endothelial cells, lying on the basal lamina. The media consists of elastic 
fibers and interposed muscular cells, collagen, and ground substance. The elastic fibers give 
distensibility to the aorta and function in cooperation with the heart, maintaining the aortic 
pressure during diastole, while collagen gives tensile strength to the aortic wall. The 
adventitia is, on the other hand, the strength layer of the aorta, maintaining aortic integrity 
and preventing it from deformation or rupture.  
Aneurysm is defined as a permanent localized dilatation of the aorta, involving at least a 
50% increase in diameter compared with the normal measure. All three layers of the aorta 
must be present at the wall of the aneurysm. The incidence of thoracic aortic aneurysm 
(TAA) is about 10/100 000/y (1). Women and men have a similar incidence, but the age at 
diagnosis is higher in women than in men (mean age, 75.9 vs. 62.8 years) (1). 
Aortic dissection (AoD) is a disruption of the media layer of the aorta with bleeding 
within and along the aortic wall. It can occur with or without aneurysm being present. 
Because of the high mortality associated with AoD, the exact incidence is difficult to define. 
Population-based studies suggest it to be 2–3.5/100 000/y. Mean age at presentation is about 
63 years with a slight male predominance (65%) (2). 
The pathology associated with TAAs and dissections is termed as medial degeneration, 
which is characterized by disruption and loss of elastic fibers and increased deposition of 
proteoglycans. There are also areas of smooth muscle cell loss in the medial layer. 
Atherosclerosis can be present in the thoracic aorta, but these changes are usually 
superimposed on medial degenerative disease. Some inflammatory cell infiltration has also 
been found in these diseases (2).  
Penetrating atherosclerotic ulcer (PAU) and IMH are variants of AoD in which blood 
enters between the layers of the aortic wall. In contrast to dissection, however, there is no 
false lumen formation; instead, the blood coagulates and forms a hematoma. Whether the 
IMH results from rupture of the small vasa vasorum located in the medial layer of the aorta 
or from a small intimal tear is still controversial. When present, penetrating ulcers often 
arise in the areas where the atherosclerosis is most predominant. 
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder. It 
predisposes patients to aortic pathology, especially to aortic aneurysm and eventually to 
AoD. In 2010, Loeys et al. (3) defined the revised set of criteria for the diagnosis of MFS. It is 
caused by mutation in the FNB1 gene on chromosome 15. The gene encodes fibrillin 1 
glycoprotein, which is essential for the formation of elastic fibers found in connective tissue, 
provides a scaffold for elastin deposition in the extracellular matrix, and serves as a 
regulator of TGF-β (transforming growth factor beta) signaling (4). In MFS, typical 
pathological findings in the vessel wall are disorganization and fragmentation of elastin 
microfibrils. Virtually every patient with the syndrome shows evidence of aortic pathology 
during their lifetime. Other typical manifestations of the disease are, for example, bone 
overgrowth, joint laxity, ectopia lentis or lens dislocation, and valvular diseases. It is 
estimated that about 50% of patients under 40 years of age with AoD have a history of MFS 
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(2). Without treatment, the prognosis of the disease is poor. In the early 1970s, mean age at 
death of these patients was 32±16 years, and the median (50%) cumulative probability of 
survival was only 48 years (5). The life expectancy has, however, increased >25% since then, 
and the mean age at death was 41±18 years in 1993, and the median (50%) cumulative 
probability of survival was 72 years (5). This increase is partly explained by overall 
improvement in life expectancy but also by benefits from modern cardiovascular surgery 
and maybe by a greater proportion of milder cases because of greater diagnostic capture. 
Loeys–Dietz syndrome (LDS) is a rare, autosomal dominant aortic aneurysm syndrome, 
which includes involvement of many other systems (6,7). The syndrome results from 
mutations in TGF receptor I or II genes (TGFBR1 or TGFBR2), and the diagnosis is 
confirmed by mutational analysis of these genes. Characteristic findings are marked arterial 
tortuosity or aneurysm formation, hypertelorism, and bifid uvula or cleft palate (Figure 1a 
and 1b). The vascular disease is very aggressive, and if left untreated, associated with a 
mean age at death of 26 years (7). The majority of patients have an aortic root aneurysm 
leading to AoD. 
 
Figure 1. Loeys–Dietz syndrome. (a) Marked tortuosity of the left vertebral artery. (b) 
Aneurysmal dilatation of the ascending aorta and acute DeBakey type I, Stanford type A 
dissection. 
 
Ehlers–Danlos syndrome is a rare autosomal dominant disorder characterized by easy 
bruising, characteristic facial features, and rupture of arteries, uterus, and intestines (2). Most 
fatal complications are attributable to arterial dissections or ruptures involving the thoracic 
or abdominal aorta. Life expectancy is reduced, and mean lifespan is only 48 years (2). 
Turner syndrome is defined as complete or partial absence of one sex chromosome, and 
the most common karyotype is 45,X. These patients have increased cardiovascular 
mortality, especially AoD (2). However, the majority of dissections in women with Turner 
syndrome occur in patients with known risk factors for dissections such as bicuspid aortic 
valve, coarctation, or systemic hypertension. 
Bicuspid aortic valve is found in 1–2% of the population and is the most common 
congenital abnormality affecting the aorta (2). It can be inherited as an autosomal dominant 
condition and is associated with TAA formation. As many as 15% of patients with AoD 
have bicuspid aortic valves (2). 
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In adult patients with an aberrant right subclavian artery, the aorta is usually pathologic 
and prone to dilate, dissect, and rupture (2). In these patients, the right subclavian artery 
arises as a fourth branch from the aorta and courses behind the esophagus. 
Coarctation of the aorta (CoA) is usually treated soon after birth, but these patients can 
present later in life with multiple problems such as heart failure, intracranial hemorrhage, 
hypertension aneurysm, or AoD. The incidence of coarctation is 40–50 /100 000 live births (2). 
Takayasu arteritis is an idiopathic T-cell–mediated vasculitis involving the aorta and its 
branches (2). The incidence is about 2.6/1 000 000 persons. The disease affects women 10 
times more often than men, and the age of onset is usually under 40 years. The vascular 
involvement is characterized by either stenosis or aneurysm formation including aortic 
aneurysms, most commonly in the descending thoracic aorta (DTA). 
Giant cell arteritis (GCA) is a vasculitis involving the aorta and its branches. In contrast 
to Takayasu arteritis, patients tend to be older, over age 50 years, and the incidence is about 
20/100 000 persons. Aortic involvement, namely AoD or aneurysm, has been found in 18% 
of patients with GCA (2). 
 Infectious arteritis resulting from bacterial, fungal, viral, spirochetal, or tubercular 
organisms can also lead to aneurysm formation in the aorta, although it is very rare. 
Infection of the aorta may arise from direct spread from adjacent structures, e.g., 
mediastinitis or abscess, septic embolus arising from bacterial endocarditis, or 
hematogenous dissemination of microbes in the setting of sepsis or intravenous drug abuse 
(2). 
Overall, known risk factors for development of AoD are conditions that result in aortic 
medial degeneration or that place extreme stress on the aortic wall. Up to 75% of patients 
have hypertension, which is often uncontrolled (2). Genetic syndromes and inflammatory 
conditions increase the risk, as described before. 
 
2.1.2 Clinical presentation 
Aneurysms of the thoracic aorta are usually insidious and often asymptomatic until the 
rupture. They can be diagnosed by chest x-ray or computed tomography (CT) scan 
obtained for other reasons. Aneurysm can, of course, cause compression symptoms to the 
adjacent structures. Aortic valve regurgitation may develop because of aortic root 
dilatation, and embolization of atherosclerotic debris with end-organ symptoms may occur.  
Dilatation of the aorta and aneurysm formation eventually lead to rupture of the aorta 
with massive hemorrhage or pericardial tamponade in the case of ascending aortic 
aneurysm. With rupture of an aneurysm, almost 100% of patients die, and only half of such 
patients even reach the hospital (8). 
Risk of the rupture grows markedly after the diameter of the aneurysm reaches 6 cm in 
the ascending aorta and 7 cm in the descending aorta (9). The lifetime cumulative risk of 
rupture jumps to about 40% after the diameter reaches this “hinge point”. The yearly risk of 
rupture, dissection, or death is as high as 14.1% at 6 cm.  
Acute aortic syndromes often present in a similar fashion regardless of the underlying 
pathology (AoD, PAU, IMH, or contained rupture). About 9 out of 10 patients present with 
severe, instantaneous pain that may, if the patient survives the acute phase, subsequently 
ease. Location of the pain reflects the site of disruption; dissection of the ascending aorta 
usually causes chest pain, and dissection in the descending aorta usually triggers back or 
abdominal pain (2). However, older patients or patients with MFS or who are on steroids can 
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present without pain, which needs to be remembered. Other presenting symptoms can be 
hypotension or shock (~27%), cardiac tamponade (~5%), ischemic nerve or spinal damage 
(~5%), lower extremity ischemia (~10%), or cerebrovascular accident (~8%) (2). 
Perfusion deficits, which usually result from dissection flap occlusion of the ostium of 
the side branch, have long been recognized as a common clinical manifestation of AoD. 
Pulse deficits are present in up to one third of patients (2). Mesenteric and renal ischemia are 
feared complications in case of dissection of the descending aorta as are cerebrovascular 
insults when the dissection is in the ascending aorta. 
Cardiac complications are not infrequent, especially when the ascending aorta is 
involved. Over half of patients with ascending AoD develop aortic regurgitation. The 
dissection flap may occlude the ostium of coronary arteries, and along with the 
hemodynamic stress associated with AoD, myocardial infarct may occur. Myocardial 
ischemia is present in up to 19% of patients (2). Pericardial pathology is also a relatively 
frequent complication of dissection of the ascending aorta. Pericardial fluid may collect in 
up to a third of patients, or because of rupture of the dissection directly into the 
pericardium, a cardiac tamponade can arise because of hemopericardium. Cardiac 
tamponade is diagnosed in 8–10% of patients (2). 
AoD should be classified based on anatomical landmarks because that forms the basis 
for decisions regarding surgical versus conservative management. The two most commonly 
used classification systems are the DeBakey and Stanford systems.  
The DeBakey system categorizes the dissection into one of three groups based on the site 
of origin and the extent of the dissection:  
 Type I: Dissection originates in the ascending aorta and extends to the descending 
aorta. 
 Type II: Dissection originates in and is restricted to the ascending aorta. 
 Type III: Dissection originates in the descending aorta, and the ascending aorta is 
intact. 
The Stanford classification categorizes the dissection into two groups:  
 Type A: Dissection of the ascending aorta occurs with or without dissection of the 
descending aorta. 
 Type B: Dissection is restricted to the descending aorta, and the ascending aorta is 
intact. 
Dissection of the ascending aorta is prone to lead to the cardiac complications already 
described. These complications can be fatal, and to prevent these devastating consequences, 
prompt surgical intervention is usually mandated (2). 
The natural history of IMH is variable, and the hematoma can in some cases entirely 
resolve (10%) or, in the worst case, eventually rupture. The natural course of the disease is 
difficult to predict, so surgical or endovascular treatment should usually be considered (2). 
Traumatic rupture of the thoracic aorta is usually a result of a motor vehicle accident. 
Most commonly, the aorta transects below the level of the left subclavian artery (LSA). 
Patients usually also have other trauma such as head injury, injury to the thoracic and 
abdominal organs, and multiple fractures. Patients with traumatic rupture of the thoracic 
aorta usually die where the event occurred because of massive bleeding. It is estimated that 
only ~10% of these patients ever reach a hospital and that only 2% will ultimately survive 
(2). Traumatic rupture should be corrected immediately either surgically or by endovascular 
means along with the treatment of other injuries. 
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2.1.3 Diagnostic imaging 
The diagnosis of aortic pathology and follow-up of these patients require dedicated 
imaging. Chest x-ray is usually the initial imaging method, especially in acute situations. 
The sensitivity and specificity are, however, poor in excluding aortic pathology, so other 
modalities are needed as well.  
To assist in the decision-making process, aortic imaging has certain essential 
requirements: 
1. To reliably show or exclude the aortic pathology and its location 
2. To give a reliable and reproducible estimate of aortic diameter at the level of 
pathology and also at certain points (aortic valve, sinuses of Valsalva, sinotubular 
junction, ascending aorta, arch, and descending aorta) 
3. To show or exclude aortic rupture, mediastinal hematoma, pericardial fluid, and 
continuing bleeding 
4. To show the potential extension of aortic pathology in branch vessels and 
evidence the possible end-organ injury 
 
CT has many advantages and has proven its usefulness in diagnostic workup of these 
patients. The availability of CT is common, and the ability to image the whole aorta and 
branch vessels and the short acquisition time are great advantages. Three-dimensional data 
are usually readily available, and electrocardiogram-gated techniques give motion-free 
images of the aortic root as well. The sensitivity can be as high as 100% with a specificity of 
98–99% (2). 
Magnetic resonance (MR) imaging is also very accurate in the diagnosis of aortic 
disease. However, the availability of MR is usually not as common as for CT, and the 
acquisition times are considerably longer; thus, in the acute setting, CT is usually the 
preferable imaging modality. In elective situations and in the follow-up, MR should be 
used whenever accessible, especially in younger patients, to reduce radiation dose. The 
other major advantage of MR over CT is the ability to image without contrast media. 
Ultrasound is a relatively good and reproducible method in imaging of the heart and 
aortic root. However, ultrasound is usually highly operator dependent, and the visibility of 
the other parts of the thoracic aorta is usually limited. 
Angiography is not usually considered as a primary diagnostic method in aortic 
syndromes. However, in the guidance of endovascular procedures and sometimes in 
preoperative planning, it has an invaluable role. 
 
2.2 TREATMENT OF THORACIC AORTIC PATHOLOGY 
 
2.2.1 Acute aortic syndromes  
After the definitive diagnosis of AoD or its variants (IMH, penetrating ulcer) is made, the 
first goal of the treatment is to stabilize the patient and limit the propagation of the disease 
while the decision between conservative and operative management is made. To limit the 
progression of the false lumen, the aortic wall sheer stress should be reduced. The wall 
stress is affected by the velocity of ventricular contraction, rate of ventricular contraction, 
and blood pressure. β-blockers control all three parameters and should be titrated to 
maintain the heart rate and blood pressure at the lowest tolerable levels. For most patients, 
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blood pressure between 100 to 120 mmHg and a heart rate <60 bpm are attainable (10). In 
patients who cannot tolerate β-blockers, calcium channel blockers such as diltiazem or 
verapamil should be used. If adequate blood pressure control is not achieved, vasodilators, 
such as sodium nitroprusside, should be added. If the patient is hypotensive or even 
normotensive, possible bleeding in the pericardial space, mediastinum, or pleura must be 
considered. 
The patients with dissection of the ascending aorta (Stanford type A or DeBakey type I 
or II) are at a high risk of life-threatening complications. Medical treatment alone is 
associated with a mortality of 30% by 48 hours (10). The aim of operative treatment is to 
prevent the complications associated with the dissection such as cardiac tamponade, aortic 
rupture, or end-organ ischemia. In 1966, DeBakey (11) introduced a surgical technique to 
reconstruct the ascending aorta that dramatically reduced the mortality associated with the 
disease. At present, the implantation of a composite graft, i.e., replacement of the ascending 
aorta and aortic valve, is usually recommended (10). Adjunctive methods, such as 
hypothermic circulatory arrest and selective retrograde perfusion of head vessels, have 
been used with good outcomes (10). Operative mortality at experienced centers varies 
between 15 and 35%, which is considerably lower than the 50% mortality associated with 
medical therapy (10). 
Stanford type B dissections (the disease confined to the descending aorta) are at present 
treated with medical therapy because routine operative management has no proven 
superiority over medical treatment (10,12). In the hospital, the mortality with type B 
dissections has been reported to be about 10%, and long-term survival with medical 
therapy is 60–80% at 4–5 years and 40–45% at 10 years (10). Operative treatment should be 
considered to prevent or relieve life-threatening complications, such as progression of 
dissection, aneurysm expansion, aortic rupture, and end-organ ischemia or severe pain. 
Modern surgical techniques have been presented elsewhere by Coselli et al. (13). Surgical 
repair of the descending aorta is usually done from a left thoracotomy and includes 
moderate systemic heparinization, mild hypothermia, and sequential aortic clamping. Left 
heart bypass is often used to reduce the spinal and visceral ischemia time. 
Endovascular repair of the aorta was first introduced in the early 1990s (14,15). The 
endovascular stent graft consists of a supporting metallic frame and a fabric attached to this 
frame. The prosthesis is packed in a catheter with an external diameter of 6–10 mm. The 
catheter is usually introduced from the groin and navigated through the arteries under 
fluoroscopic control. Once the catheter is in place, the stent graft is released by pulling 
away the sheet covering it, and the graft expands by itself, attaching to the aortic wall and 
excluding the pathologic segment away from the bloodstream. 
Unfortunately, no published randomized trials have compared the outcomes of 
endovascular stent grafting with conventional open operation. Current recommendations 
are based on observational studies and comparisons of cohorts of patients. Endovascular 
treatment has a potential advantage over open surgery because a thoracotomy incision can 
be avoided as can extracorporeal circulatory support and clamping of the aorta. Therefore, 
in-hospital mortality rates seem to be significantly lower after endovascular treatment, and 
the hospital stay tends to be shorter (16-18). However, long-term durability is still not proven, 
and the survival advantage of endovascular treatment seems to vanish after 5 years 
(endovascular vs. open, 53.4% vs. 53.3%) (17). The intersection of the survival curves may be 
partly explained by the re-operations associated with the endovascular treatment and 
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partly because older patients and patients with severe co-morbidities tend to shift to the 
endovascular group. There have also been some flaws in the design of the first-generation 
stent grafts, and there are hopes that the second- and third-generation versions will be 
more durable. 
Endovascular grafting may be well suited especially for patients with severe 
comorbidities and who thus would be poor surgical candidates. However, although 
definitive evidence of the superiority of endovascular treatment is lacking, this treatment is 
continuously gaining popularity over open surgical repair and at present is considered a 
first-line option in most centers treating these patients. Nevertheless, with younger patients, 
caution is needed because long-term durability is still unresolved and patients require 
regular and lifelong surveillance after endovascular treatment, which is quite restrictive for 
them and markedly increases their cumulative lifetime radiation dose. 
Implantation of the endovascular prosthesis requires adequate landing zones in both 
ends, and the neck above and below the pathologic segment should be at least 10 mm to 
prevent long-term complications (19). Important side branches of the aorta cannot be covered 
without serious consequences, and in certain situations where an adequate landing zone 
cannot be otherwise achieved, additional procedures such as fenestrated or branched stent 
grafts, chimney procedures, carotid(–carotid)–subclavian bypasses, or bypass of the visceral 
arteries have to be considered. These alternatives will be discussed later. 
IMH and PAU should be treated, according to the present knowledge, following the 
same principles as with dissections (2). Pure intimal defects without IMH are usually 
insidious findings and are treated as saccular aneurysms based on their maximum 
diameter. When there is IMH present with or without intimal defect, the treatment should 
be based on the anatomical location of the disease as described previously in the section 
dealing with dissections. 
 
2.2.2 Thoracic aortic aneurysms 
Once the aortic diameter reaches 6 cm, the risk of rupture increases markedly. Ruptured 
aneurysms have a very poor prognosis, and the aneurysm therefore should be treated 
before its diameter reaches this hinge point. However, in patients with connective tissue 
disorders such as LDS and MFS, the risk of complications is considerably increased even at 
smaller diameters. Thus, the current recommendation states that the aorta should be 
repaired when the diameter reaches 4.5 cm in LDS patients and 5.0 cm in MFS patients (2). 
At present, two options are available for the operative management of aneurysmal disease: 
open surgical and endovascular treatment. These can also be used in combination. 
Open surgery of the thoracic aorta is usually very demanding and requires good surgical 
expertise. The postoperative mortality can be high, and the experience of the surgeon in 
treating these patients and the volume of the center have a significant impact on survival 
(20). 
For patients with isolated aneurysm of the ascending aorta, open surgical resection and 
graft replacement are usually the recommended procedure. Patients with aortic valvular 
disease should be considered also for valve replacement at the same time (2). Only some 
anecdotal case reports have been published on the endovascular treatment in the ascending 
aorta. The present recommendations state that open surgical treatment is the first-line 
option and that endovascular treatment should be done only in combination with surgical 
procedures as hybrid operations (2). 
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Aneurysms of the aortic arch are usually associated with aneurysmal disease of the 
ascending aorta or the adjacent descending aorta. Indications for treatment are those for the 
adjacent aortic segment. At present, endovascular treatment has not been officially accepted 
for treatment of aortic arch aneurysms. Therefore, the aortic arch is usually replaced with a 
synthetic graft, and the arch vessels are attached to the graft using a patch of aorta or using 
a graft containing three branches. Also, an “Elephant trunk” procedure has been employed 
when it is necessary to provide a landing zone for the endovascular graft at the descending 
aorta. However, experience is accumulating with operative procedures in which arch 
vessels are translocated or bypassed from the ascending aorta and an endovascular graft is 
then placed in the aortic arch covering the diseased segment (2). Open surgery requires 
cardiopulmonary bypass and hypothermia, so these kinds of hybrid procedures are 
tempting alternatives especially for patients who are otherwise considered to be poor 
surgical candidates. 
At the descending aorta, open surgical treatment is usually done from a posterolateral 
thoracotomy (13). The majority of complications result from the end-organ ischemia during 
the operation, so sequential aortic clamping, hypothermia, and systemic heparinization are 
used to maximize organ protection. Left heart bypass can serve to reduce the spinal and 
visceral ischemia time. Segmental artery reattachment at the level of T8–L1 is also 
recommended as well as cerebrospinal fluid drainage to prevent neurological 
complications resulting from spinal ischemia. Endovascular treatment is gaining popularity 
because the operative and postoperative mortality and morbidity seem to be significantly 
lower than those of open surgery (16,17,21-24). However, long-term durability is still unproven, 
and because the mortality after open surgery of patients under age 60 years seems to be 
relatively low (25), caution is needed when considering endovascular treatment for younger 
patients. 
Implanting the endovascular prosthesis has some anatomical requirements to be 
successful. The access vessels must be of suitable size (>8 mm diameter), and pronounced 
elongation and calcification of iliac vessels increases the risk of complications. However, 
these obstacles can be overcome with the use of conduits, i.e., short stubs of synthetic 
prosthesis implanted directly into the iliac artery or aortic bifurcation. To securely seclude 
the aneurysm from the bloodstream, the proximal and distal necks, i.e., the zone where the 
stent graft attaches to the aortic wall, must be at least 15 mm or longer. Continuous blood 
flow directly from the aorta to the aneurysm, the so-called endoleak (Table 1, Figure 2), 
results in further aneurysm growth and eventual rupture if left untreated. Important side 
branches of the aorta, such as the brachiocephalic trunk (BT), carotid arteries, or renal or 
mesenteric arteries, cannot be covered without serious consequences. Even covering of the 
LSA can expose the patient to neurologic complications, such as stroke, spinal ischemia, 
and paraparesis (26,27). Thus, if the length between the aneurysm and an important side 
branch is less than 15 mm, surgical repair must be considered or some additional 
procedures be performed to increase the length of the landing zone. 
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Table 1. Classification of endoleaks 
 
Type Cause of perigraft flow Treatment strategy 
I Inadequate seal proximal to distal graft 
attachment site 
Should be repaired when diagnosed. 
II Retrograde aortic branch arterial blood flow 
into aneurysm sac 
May spontaneously thrombose. If aneurysm is 
expanding, embolic occlusion of branch artery is 
indicated. 
III Structural failure of endograft Should be repaired when diagnosed. 
IV Stent graft fabric porosity Usually is resolved, with reversal of 
anticoagulation. 
V Expansion of aneurysm without 
demonstrable endoleak, so-called 
endotension 
Reline the endograft with a second endograft. 
Adapted from Hiratzka et al. (2). 
 
 
Figure 2. Type III endoleak. (a) Axial image at the aortic arch level. Continuous blood flow 
through the graft fabric directly into the aneurysm. (b) Coronal and volume rendering technique 
reconstructions of the same situation. (d) No visible fractures in the metallic skeleton of the 
stent graft.  
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2.2.3 Hybrid operations 
If coverage of the LSA is anticipated, the patency of the contralateral subclavian artery must 
be confirmed, and verification that vertebral arteries communicate in the basilar artery 
must be done before implantation of the stent graft. However, as stated before, these 
patients may be at increased risk of postoperative neurologic complications. 
Revascularization is most commonly done with a bypass operation from the left carotid 
artery. When the left carotid artery must also be covered, a carotid–carotid–subclavian 
bypass is a feasible alternative. Additionally, when treating aortic arch aneurysms and the 
innominate brachiocephalic artery has to be covered, all of the arch vessels can be bypassed 
from the ascending aorta before stent graft implantation (Figure 3). 
  
Figure 3. Stent grafting of the aortic arch after de-branching of the supra-aortic vessels with a 
Y-prosthesis and left carotid–left subclavian bypass.  
 
Hybrid techniques have been used with noteworthy results (28), as the reported primary 
success rate has been 69–100% with an overall mean perioperative mortality of 9% and 
perioperative morbidity (strokes excluded) of 14%. In published reports, the overall mean 
stroke rate has been 7% and the spinal cord ischemia rate 0.5%. There are, unfortunately, no 
randomized controlled studies comparing these two treatment options, so the results are 
based on small patient series. Regardless, these figures are at the same level with the open 
surgical treatment, but direct comparison is very difficult because of the heterogeneity of 
the patient populations. An endovascular option has been considered as good for patients 
who are at high surgical risk, which distorts the analysis. 
 Another option to handle aortic arch vessels is to use either fenestrated (29) or branched 
(30-33) stent grafts. Fenestrated stent grafts are customized prostheses tailored individually for 
13 
 
 
each patient. Fenestrations, i.e., holes in the fabric, are placed according to the pre-
procedural imaging so that after implantation of the main prosthesis, the stent grafts are 
placed in the side braches securing adequate blood flow in the branches and excluding the 
aneurysm away from the bloodstream.  
In branched grafts, there is a side branch or branches implanted in the main prosthesis, 
and these can be stent grafted after the deployment of the main body. This approach allows 
more secure sealing of the side branch stent grafts and reduces the risk of endoleak. These 
methods have also been used with success but are still evolving, and published series are 
small. Definitive analysis of the safety and feasibility of fenestrated or branched endografts 
is still lacking. These kinds of endografts are expensive, and because they are custom made 
for each patient, cannot be used in acute situations. 
The so-called chimney procedure may be a way to reduce expenses and make 
endovascular stent grafting of the aortic arch available for acute situations and possible 
without extra-anatomical surgical revascularization of the vessels (34,35). In this technique, 
covered stents are deployed parallel to the main aortic stent graft, protruding somewhat 
proximally, like a chimney, to preserve flow to vital side branches covered by the aortic 
stent graft. Use of a chimney graft makes it possible to employ standard off-the-shelf stent 
grafts to instantly treat lesions with inadequate fixation zones, providing an alternative to 
fenestrated stent grafts in urgent cases and in aneurysms with challenging neck 
morphology. So far, only small case series have been published on this technique. It may be 
a feasible alternative, but it remains somewhat experimental. 
Intraoperative fenestration has also been tested and used successfully as an alternative 
for hybrid operations or prefabricated fenestrated grafts (36-39). As with the chimney 
operation, individually designed stent grafts are not needed with this technique. The 
fenestration is created after the stent graft is implanted by puncturing the fabric with a 
needle or burning a hole with a laser or radiofrequency probe. The hole is then sequentially 
dilated with percutaneous transluminal angioplasty (PTA) balloons until it reaches 
adequate size, and it is then stent grafted. Because the dilatation results in tearing the fabric 
material, some concerns remain about the durability of this approach. 
2.2.4 Follow-up 
Patients treated with endovascular prostheses need lifelong surveillance to prevent late 
complications(40). Long term durability of first generation stent grafts was actually a 
disappointment and although the materials and design of the stent graft have improved 
over the years, there is still risk of graft material break down, which leads to type III 
endoleak. As the stent graft itself is attached to the aortic only by its radial force, there is 
also a potential for development of type I endoleak, if the native aorta continues to dilate.   
The surveillance regimen varies between the institutions, but usually the protocol 
involves imaging either immediately or one month after operation, at 3-6 months and 1 
year after the procedure. Surveillance is then done on an annual basis. Standard chest X-ray 
imaging and CT-angiography are recommended imaging modalities (40). 
Direct costs are somehow difficult to estimate and direct estimations of long term cost 
benefits of endovascular treatment of thoracic aorta compared to the open surgery, haven’t 
been done. The initial costs of the endovascular treatment seem to be lower (41). However, 
from the studies comparing endovascular treatment of abdominal aorta between the open 
surgery, the cost benefit of the endovascular treatment seems to diminish in two years (42-44). 
This is due to the need for regular surveillance and reoperations.  
14 
 
 
The radiation exposure of a single follow up CT is at acceptable levels, when compared 
to increased mortality and morbidity associated with the aneurysmal disease itself and also 
when compared to the mortality and morbidity associated with open surgical treatment (45). 
Nevertheless, repeated CT-scans over the years may significantly increase the risk of cancer 
and one has to bear this in mind especially when treating younger patients. The precise risk 
is somehow difficult to estimate, but it has been estimated that in a patient with life 
expectancy over 15 years, the surveillance program leads to a lifetime risk increase in 
radiation-induced leukaemia and solid-tumor cancer >2.7% (45). 
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3 Aims of the study 
 
The aim of this study was to evaluate the present state of endovascular treatment of 
thoracic aortic diseases and develop it further to reduce expenses and make it more 
available. 
The more specific aims were as follows: 
1. To evaluate how different fabrics of stent grafts respond to dilatation after 
fenestration 
2. To test and develop a method for intraoperative fenestration of a stent graft in an 
animal model 
3. To evaluate the treatment outcome of degenerative TAAs in consecutive Finnish 
patients 
4. To evaluate the utility of hybrid endovascular and open surgical treatment of 
aortic pathology in connective tissue disorders 
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4 Materials and methods 
 
4.1 IN VITRO TESTS 
 
Commercially available stent grafts from three manufacturers were tested: Zenith (William 
Cook, Baereskov, Denmark); Gore TAG (W.L. Gore, Flagstaff, AZ, USA); and Valiant, 
Talent, and Endurant (Medtronic Inc., Minneapolis, MN, USA). For the first test, a small 
hole was created with a 22-gauge needle, and the hole was sequentially dilated with 2.5-
mm and 4-mm coronary PTA balloons (Maverick; Boston Scientific, Natick, MA, USA) and 
7-mm and 10-mm peripheral PTA balloons (Opta Pro Cordis, Miami Lakes, FL, USA). Stent 
grafts were manipulated by hand, and balloons were placed manually through the hole 
created with a needle. With each balloon, the pressure was gradually increased until the 
balloon was fully open with no waist caused by the prosthesis. 
The prospective goal was to create a fenestration with a diameter of 10 mm. 
Fenestrations were assessed visually by two observers and recorded on x-ray images. For 
the second test, a hole created in the fabric with the needle was dilated with a 5-mm cutting 
balloon (Boston Scientific). Results were recorded as before. Residual diameter stenosis 
caused by the fabric was measured from x-ray images of the balloon. A 6-mm/38-mm 
Advanta V12 (Atrium Medical; Hudson, NH, USA) stent graft was placed through the 
fenestration and dilated. The joint between the main prosthesis and the side branch stent 
graft was assessed visually for evidence of possible gaps. Finally, an additional fenestration 
was created in the Talent prosthesis, puncturing the hole as close as possible to the stent 
strut. 
 
4.2 IN VIVO PIG MODEL 
 
Three domestic pigs, weighing 50–60 kg each, were anesthetized. Both femoral arteries 
were punctured and an 8F sheath introduced. Both renal arteries were catheterized under 
fluoroscopic control (GE Innova IQ 3100 Excellence, GE Healthcare, Waukesha, WI, USA) 
from the left groin, and 5 mm/20 mm PTCA (percutaneous transluminal coronary 
angioplasty) balloon catheters (Maverick, Boston Scientific, Natrick, MA, USA) were 
advanced into both renal arteries. A 16-mm iliac extension stent graft (Endurant, 
Medtronic, Minneapolis, MN, USA) was deployed in the abdominal aorta covering the 
renal arteries in the first pig, and a Talent (Medtronic) stent graft in the second and the 
third pigs. Thereafter, a Channel steerable sheath (CR Bard, Murray Hill, NJ, USA) was 
advanced into the aorta from the right groin. This device with an 8F or 9F inner diameter is 
intended to access the left atrium for purposes of diagnosing and treating left-sided atrial 
arrhythmias. The device has a flexible tip that can be bent at a 0–180° angle, and the sheath 
remains in the precise position once set. The steerable sheath is necessary to point the 
needle in an exact manner towards the renal artery ostium and to give support to the re-
entry catheter during needle penetration of the resilient stent graft fabric. Balloons in the 
renal arteries were inflated and served as markers when the stent graft was punctured with 
an Outback re-entry catheter under the guidance of fluoroscopy (Cordis, Miami Lakes, FL, 
USA). The Outback catheter is a 6F system that uses orthogonally oriented radiopaque 
markers, and the main indication of the device is to aid the re-entry of the dissecting wire 
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into the true lumen distal to an occlusion in the peripheral arteries. In the experiment, the 
22-gauge re-entry needle was directed towards the arterial orifice.  
Once the deflation of the balloon in the renal artery indicated successful puncture, a 
0.014-inch guide wire was advanced through the fabric into the renal artery. The Outback 
device was changed to a PTCA balloon and the fenestration sequentially dilated to 5 mm. A 
6-mm balloon expandable renal stent (Racer, Medtronic) or a 6-mm covered stent (Jostent, 
Abbot Vascular Instruments, Rangendingen, Germany) was placed in the fenestration to 
keep it patent. After the procedure was completed, the pigs were euthanized and 
autopsied. 
 
4.3 DEGENERATIVE ANEURYSMS 
 
4.3.1 Patient population 
From June 1998 to March 2010, 158 consecutive patients with diseases of the DTA 
underwent endovascular stent graft placement either alone or in combination with surgical 
treatment in three Finnish university hospitals. Of these, 69 patients (58 men; mean age 71.7 
years, range 54–90) had an aneurysm of the descending aorta and were included in this 
retrospective analysis (Helsinki University Hospital, n=19; Kuopio University Hospital, 
n=37; and Oulu University Hospital, n=13). Medical records, radiological imaging studies, 
and national death records were collected and analyzed on an intention-to-treat basis. Table 
2 gives the baseline characteristics of the study sample. 
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Table 2. Baseline characteristics of patients who underwent stent grafting of the descending 
aorta in three Finnish university hospitals from 1998 to 2010 
 
Demographics 
 Age, y 71.7 (54–90) 
   <60  3 (4%) 
   60–79  56 (81%) 
   >80  10 (15%) 
 Male  58 (84%) 
Risk factors  
 Hypertension 54 (78%) 
 Coronary artery disease 34 (49%) 
 Renal failure 19 (28%)  
 Cerebrovascular disease 15 (22%) 
 Diabetes 14 (20%) 
 Congestive heart failure 4 (6%) 
 COPD 16 (23%) 
American Society of Anesthesiology 
Classification 
 
 3 34 (49%) 
 4 30 (43%) 
 5 2 (3%) 
TAA classification (Crawford) (46)  
 Type I 49 (71%) 
 Type II 4 (6%) 
 Type III 5 (7%) 
 Type IV 0 (0%) 
 Type V 10 (14%) 
 Missing information 1 (1%) 
Proximal landing zone (Ishimaru) (47)  
 0: Proximal to the BT 2 (3%) 
 1: BT to left CCA 1 (1%) 
 2: Left CCA to LSA 9 (13%) 
 3: LSA to T4 level 19 (28%) 
 4: Distal to T4 level 36 (52%) 
BT, brachiocephalic trunk; CCA, common carotid artery; COPD, chronic obstructive pulmonary 
disease; TAA, thoracic aortic aneurysm 
 
Fifteen (21.7%) patients presented with acute symptoms, either aneurysm rupture or 
uncontrollable pain, that were considered aneurysm-related. Fifty-four patients were 
treated on an elective basis, which was indicated if the DTA diameter was ≥6.0 cm or 
displayed a growth rate ≥1 cm/y. Patient selection, evaluation, and procedures were done in 
close cooperation with interventional radiologists and cardiovascular surgeons. At the 
beginning of the study period, endovascular treatment was considered as an option for 
high-risk surgical patients, but later on, the trend shifted more toward endovascular 
treatment. If there were factors hampering the endovascular treatment (e.g., short proximal 
or distal neck, difficult access), hybrid procedures were considered as second-line options. 
 
4.3.2 Preoperative imaging 
Computed tomographic angiography (CTA) with multiplanar reformatting of the entire 
aorta was performed in all patients to evaluate the location, diameter, and length of the 
aneurysm; the diameter of the landing zones; and the suitability of the access routes. Stent 
graft diameters were also calculated from the CTA images and were oversized by 10% to 
15% according to the manufacturers’ instructions. 
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4.3.3 Operations 
Four different stent grafts were used: TAG (W. L. Gore & Associates, Inc., Flagstaff, AZ, 
USA), Talent and Valiant (Medtronic Vascular, Santa Rosa, CA, USA), and Zenith (Cook 
Inc., Bloomington, IN, USA). 
If coverage of the LSA was required to achieve an adequate proximal neck (≥1.5 cm; 
n=14), cerebral imaging determined the status of the intracranial circulation. Coverage of 
the LSA was required when the left vertebral artery was dominant (n=9); revascularization 
was done by carotid–subclavian bypass (n=8) or transposition (n=1). The LSA was covered 
without additional surgery in 5 patients (3 elective and 2 acute). If the left common carotid 
artery was to be covered by the stent graft (n=6), a carotid–carotid–subclavian bypass was 
performed. Revascularization of the supra-aortic vessels was usually performed 2 to 3 days 
before stent grafting.  
Stent grafts were deployed under fluoroscopic guidance using standard techniques and 
general, spinal, or epidural anesthesia. During the last 2 to 3 years, if the proximal landing 
zone was at the level of the aortic arch, rapid pacing was used to aid the deployment of the 
stent graft at the precise position. To prevent spinal cord ischemia during or after the 
operation, spinal drainage was employed in cases with a lengthy covered segment of the 
aorta, especially if the patient had an abdominal aortic stent graft or a Y-prosthesis. When a 
type I or III endoleak was detected during the procedure, additional stent grafting or coil 
embolization was performed as necessary. 
 
4.3.4 Definitions 
All data are presented in accordance with current reporting standards (48). Aneurysms were 
classified according to the Crawford classification (46) and proximal landing zones according 
to the Ishimaru classification (47). 
Technical success was defined as achieving access to the arterial system and deployment 
of the graft with secure fixation, absence of type I or III endoleak on postoperative imaging, 
and a patent endoluminal graft. Primary technical success was reported on an intention-to-
treat basis. A major complication was defined as an event requiring major therapy, 
unplanned increase in the level of care, prolonged hospitalization, or leading to permanent 
adverse sequelae or death. 
 
4.3.5 Follow-up 
Patient follow-up included clinical examination, standard chest radiography, and CTA or 
magnetic resonance angiography (MRA) in selected cases at 2 to 4 days after operation, at 3 
and 12 months postoperatively, and annually thereafter. If a type I or III endoleak was 
found on the immediate postoperative CTA, another CTA was scheduled for 2 weeks to 1 
month after the primary operation to ensure that the endoleak had resolved. If this did not 
happen, additional procedures were performed as necessary. 
 
4.3.6 Statistical methods 
Logistic regression was employed to identify predictors of 30-day mortality. The results are 
presented as odds ratios (ORs) with 95% confidence intervals (CIs). The Kaplan–Meier 
method was used to estimate survival. P<0.05 was considered to indicate statistical 
significance. Statistical analysis was performed with IBM SPSS Statistics software (version 
19; IBM Corporation, Somers, NY, USA). 
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4.4 MARFAN AND LOEYS–DIETZ SYNDROMES 
 
In three tertiary care centers, 158 consecutive patients were treated for thoracic aortic 
pathologies during 1998–2010 with endovascular stent grafts. In this patient population, 1 
patient had LDS and 2 patients had MFS. The patient baseline characteristics are presented 
in Table 3. 
 
Table 3. Baseline characteristics of patients with connective tissue disorder 
 
Pt. Age Gender Diagnosis Symptoms and findings 
1 39 Female LDS Dilatation of aortic root, aortic dissection, hypertelorism, bifid 
uvula, marked tortuosity of carotid and vertebral arteries, 
mutation in TGF-β receptor 1 gene 
2 25 Female Marfan Aortic root dilatation, ectopia lentis 
4 22 Male Marfan Aortic dissection, FNB1 mutation, mitral valve prolapse, pectus 
excavatum, scoliosis 
 
4.5 APPROVAL OF ETHICS COMMITTEE AND THE NATIONAL ANIMAL 
EXPERIMENT BOARD 
 
Project approvals were obtained from the ethics committee of Kuopio University Hospital 
(September 2009) and from the National Animal Experiment Board (March 2010).  
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5 Results 
 
5.1 PATTERNS OF FABRIC DISRUPTION AFTER BALLOON DILATATION 
OF THE FENESTRATION 
 
5.1.1 Fenestration with a standard balloon 
Results from the radiologic and visual assessments after standard balloon dilation are 
summarized in Figure 4. Creation of a fenestration was easiest with the Talent and Valiant 
grafts. There was no residual stenosis at the balloon profile after dilation with a 4-mm 
diameter balloon up to 26 atm (Talent) and 24 atm (Valiant). The fenestration widened with 
low pressure during dilation with 7-mm and 10-mm balloons. Gore TAG and Endurant 
grafts resisted 2.5-mm and 4-mm balloon dilation. The waist of the balloon disappeared 
after dilation with a 7-mm balloon up to 12 atm, and there was no difficulty widening the 
fenestration up to 10 mm. The fabric of the Zenith stent graft was most resilient and 
resisted, to some degree, all dilation attempts; a residual diameter stenosis of 29% remained 
even after dilation with the largest 10-mm balloon. 
Visually, the hole created in the Gore TAG endoprosthesis was very clean-cut. The hole 
was slightly oval, and the edges were smooth with no indication of fraying. In Talent and 
Valiant prostheses, the tears were oriented transversally, but the edges were round and 
showed only slight fraying. The hole in the Zenith graft was round, and there was 
moderate fraying on the edges; the tear in the Endurant graft was oriented longitudinally, 
and there was heavy fraying on the edges. 
 
5.1.2 Fenestration with a cutting balloon 
Technically, traversing the fabrics was more challenging with the cutting balloon compared 
with standard coronary balloons. The visual appearance of various fabrics after dilatation 
with a cutting balloon is presented in Figure 5. Talent, Valiant, and Endurant fabrics 
responded favorably to dilation with the cutting balloon, and the balloon was fully open at 
6 atm. Gore TAG and Zenith stents needed dilation up to 10 atm, however, before the waist 
of the balloon disappeared. Dilation with the cutting balloon resulted in fringed edges in all 
stent grafts except Gore TAG, in which the hole was oval, and the edges were relatively 
smooth. 
 
5.1.3 Side branch stent graft 
On visual inspection, good apposition of the side branch stent graft to the main prosthesis 
was achieved in all fabrics if the hole was not close to metallic stent struts. If the 
fenestration was located in close proximity to a stent strut, the metallic structure could 
obstruct the hole so that the side branch stent graft could not be fully opened; tight sealing 
of the fenestration was not accomplished. 
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Figure 4. Residual stenosis and visual appearance of various fabrics after sequential dilation with a 
standard PTA balloon. 
 
 
 
 
 
Figure 5. Visual appearance of various fabrics after dilation with a cutting balloon. 
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5.2 IN VIVO FENESTRATION OF AORTIC STENT GRAFTS 
 
In all three cases, the steerable sheath gave enough support that it was easy to maneuver to 
point towards the ostium of the renal arteries. 
In the first pig, successful needle puncture and the introduction of a 0.014-inch guide wire 
through an Endurant stent graft were achieved in both renal arteries. Unfortunately, the 
available guide wire (ATW, Cordis) did not give enough support for the 3-mm PTCA balloon 
(Maverick, Boston Scientific), and we could not advance the balloon through the fenestration. In 
the second pig, using a Talent stent graft and a heavy-duty guide wire (Mailman, Boston 
Scientific), a low-profile 1.5-mm PTCA balloon (Maverick, Boston Scientific) was advanced into 
the fenestration, which was then sequentially dilated to 5 mm. A 6-mm/18-mm (Racer, 
Medtronic) renal stent was delivered into the right renal artery and a 6-mm/28-mm (Jostent, 
Abbot Vascular Instruments) balloon-expandable stent graft was delivered into the left kidney. 
During the experiment with the third pig, the needle of the Outback device fractured, and the 
procedure had to be discontinued. In the case of completed intervention, the ischemia time was 
24 min and 55 min for the right and left kidneys, respectively. The left kidney showed clear 
signs of ischemic injury when autopsied (Figure 6). No hematoma was found around the aorta 
in any of the three pigs, indicating that there was no retroperitoneal bleeding, despite several 
punctures through the stent graft with the Outback needle.  
Visual inspection of the stent grafts showed no damage to the graft material despite several 
punctures. 
 
Figure 6. The left kidney was pale and appeared nonviable, indicating a definitive ischemic injury. No 
signs of hematoma or bleeding were seen around the aorta. 
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5.3 ENDOVASCULAR TREATMENT OF DEGENERATIVE ANEURYSMS OF THE 
DESCENDING AORTA 
 
5.3.1 Primary success 
Technical success was achieved in 44 (81.5%) of the 54 elective patients; there were nine type I 
endoleaks, which were graded as mild and assumed to resolve without any further procedures. 
One patient died of pulmonary embolism at the beginning of the operation before stent 
grafting.  
Among the 15 patients undergoing urgent repair, technical success was achieved in 11 
(73.3%); there was one type I endoleak and three access failures due to narrow iliac arteries. In 1 
patient, a new attempt with a conduit was planned, but unfortunately this patient died of 
aneurysm rupture beforehand. Two remaining patients were deemed to be poor surgical 
candidates, and no additional attempts were planned.  
Two TAA patients who also had aneurysms of the ascending aorta were treated with an 
elephant trunk in the first stage and then the stent graft repair of the descending aorta.  
Spinal drainage was used in 12 (17.4%) patients; in 1 (1.4%), spinal drainage was employed 
as a rescue therapy after the operation due to paraparesis. The use of elective spinal drainage 
was associated with >200 mm coverage of the aorta (72% vs. 22%, P=0.04).  
 
5.3.2 Complications  
Major complications occurred within 30 days after the procedure in 10 (18.5%) patients who 
underwent elective repair (Table 4). Paraparesis occurred postoperatively in 3 patients (3/69, 
4.3%); 2 were permanently paralyzed. Paraparesis was not associated either with the extent of 
aortic repair or with the covering of the LSA, with or without revascularization of the arch 
vessels.  
Stroke occurred in 3 (4.3%) patients, all of whom had aortic arch vessel reconstructions (1 
carotid–carotid–subclavian bypass and 2 carotid–subclavian bypasses). One of these patients 
had a cerebellar infarction, and two had infarctions of the right middle cerebral artery territory. 
All patients with postoperative stroke had a heavily atheromatous ascending aorta. No 
neurological complications occurred among the 3 elective patients who had the LSA covered 
without revascularization. 
On elective patient suffered an iliac artery rupture, and 3 had myocardial infarctions 
(including one paralysis patient). 
In the 15 acute patients, major complications occurred in 7 (47%) patients, and all were fatal. 
In addition to 4 aneurysm ruptures (described below), there were individual cases of fatal renal 
dysfunction, pneumonia, and an ischemic brain insult. 
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Table 4. Complications 
 
 n 
 Paraplegia 3 
 Stroke 3 
 Myocardial infarction 3 
 Access artery rupture 1 
 Pulmonary embolism 1 
 Renal dysfunction 1 
 Pneumonia 1 
 Hypoxia-induced brain damage/pyelonephritis 1 
 Elective/acute 10/7 
Mortality  9/69 (13.0%) 
 Elective 2/54 (4.3%) 
   Pulmonary embolism 1 
   Multiorgan failure 1 
 Acute 7/15 (46.7%) 
   Aneurysm rupture 4 
   Unrelated to aorta 3 
 
5.3.3 Thirty-day mortality  
The 30-day mortality was 13.0% (9/69), with a striking difference between the urgent group 
(46.7%, 7/15) and the elective group (3.7%, 2/54; P<0.01). As noted above, 1 patient died during 
an elective procedure because of a pulmonary embolism. Another elective patient died 2 days 
after the procedure from multiple organ failure consequent to iliac artery rupture. 
Among the acute patients, 4 experienced aneurysm rupture during the immediate 
postoperative period (27% aortic-specific mortality). Two of them died at 4 and 13 days, 
respectively, after the primary operation despite apparently good primary results. The other 
two were patients with access failure. One of these patients was in critical condition, and no 
other treatment attempts were planned; the patient died 11 days later due to aortic rupture. The 
other patient had a new attempt planned but died of aortic rupture 4 days after the initial 
attempt. The 3 further deaths were unrelated to their aortic pathologies.  
Perioperative blood loss (OR 3.2, 95% CI 1.3 to 7.5, P=0.009) and patient age >75 years (OR 
6.0, 95% CI 1.1 to 31.7, P=0.03) were independent predictors of 30-day mortality. There were no 
statistically significant differences in death rates among the three centers. 
 
5.3.4 Early endoleaks 
Ten (19%) patients had type I endoleaks at their first control CTA immediately after the 
operation. In 5 patients, the endoleaks resolved spontaneously without any further 
intervention. Among the 5 persistent endoleaks, 2 patients had coil embolization. In the first 
patient, the proximal end of the stent graft was embolized. The endoleak had disappeared on 
the 3-month CT, but it later reappeared, along with an increase in the diameter of the aneurysm. 
The endoleak was successfully embolized by placing coils between the stent graft and aortic 
wall 3.5 years after the primary operation.  
In the second embolotherapy patient, there was insufficient sealing of the distal end of the 
stent graft due to a short distal neck, and the aneurysm continued to grow. After an ineffective 
attempt at embolization, additional stent grafting at the distal end and a bypass operation of the 
visceral arteries was performed 2.5 years after the primary operation.  
Two further type I endoleak patients underwent additional stent graft placement at the 
proximal landing site; in one, a carotid–subclavian bypass was necessary due to a short 
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proximal neck. The 5th patient with a persistent type I endoleak was lost to follow-up; he 
presented with aneurysm rupture because of a significant increase in the aortic diameter from 
the baseline 35 months after the primary procedure. He underwent a successful re-do stent graft 
repair.  
 
5.3.5 Late endoleaks 
Two patients who had no signs of endoleak previously developed late type I endoleaks at 12 
and 52 months after the primary operation, respectively. Both were successfully treated, one 
with additional stent grafting at the distal end and the other by coil embolization. The presence 
of late type I endoleaks detected during follow-up was not associated with survival. 
One patient developed a type III endoleak 37 months after the primary operation. At that 
stage, the patient was in poor general health and was considered inoperable; he died 91 months 
after the primary operation due to head trauma. 
 
5.3.6 Long-term follow-up 
Mean follow-up was 34.8±29 months (range 0.1–121). In that time, two graft migrations were 
noted (one Zenith and one Valiant stent graft). The only structural defect occurred in a TAG 
stent graft with type III endoleak. Altogether, eight re-interventions were performed on 7 (10%) 
patients during follow-up, as noted above. An additional 4 patients died, 1 from retrograde 
dissection of the ascending aorta 3 months after the operation, possibly because of the 
oversizing of the stent graft by 30%. In this particular patient, the aneurysm in the descending 
aorta was intact and was actually shrinking. Three of four (6%) late aneurysm ruptures (all 
elective repairs) were fatal. One patient had no signs of endoleak or aneurysm growth until she 
was lost to follow-up 2 years after the primary operation; unfortunately, the aneurysm ruptured 
10 years after the index operation, which led to her death. The 2 (3%) other fatalities were due to 
acquired infections in their aneurysms, which led to rupture at 27 and 32 months, respectively, 
after the primary operation.  
Overall survival was 72.5% at 1 year and 53.2% at 3 years (Figure 7). At the same intervals, 
the rates for freedom from aneurysm-related deaths were 88% and 83%, respectively. The rates 
for freedom from type I or III endoleaks were 84% and 81%, respectively, and 93% and 90% for 
freedom from any re-intervention, respectively. 
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Figure 7. Kaplan–Meier survival curve of all patients. 
 
5.4 HYBRID TREATMENT OF AORTIC PATHOLOGY IN CONNECTIVE TISSUE 
DISORDERS 
 
5.4.1 Loeys–Dietz syndrome 
Patient 1 was a previously healthy woman, and an acute Stanford type A, DeBakey type I 
dissection of the whole aorta was the first sign of her disease. At the same time, dilatation of the 
aortic root was noted (Figure 8a and b). The ascending aorta and aortic valve were replaced 
with a composite graft. The patient had a pericardial effusion postoperatively, which resolved 
spontaneously.  
After the first insult, rapid progression in the dilatation of the remaining aorta and also the 
subclavian artery (Figure 8c and 8d) necessitated further interventions until her whole aorta 
was replaced with surgically implanted prostheses and endovascular stent grafts. Ten weeks 
after the first insult, the supra-aortic vessels were bypassed with a Y-prosthesis originating from 
the previously implanted composite graft, and the legs were implanted onto the BT and left 
carotid artery. An additional carotid–subclavian bypass was performed in the same procedure. 
The left vertebral artery originating from the aortic arch was closed by coil embolization, and 
the proximal LSA was closed using an Amplatzer plug. The aortic arch and the entire DTA 
were sequentially stent grafted (Figure 9a and 9b). The patient made a full recovery without any 
major complications. 
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The first suspicion of LDS arose 2.5 months after the first operation, but the final results of 
genetic testing became available only 11 months after the primary insult. They confirmed the 
LDS diagnosis. 
The right subclavian artery was also dilating rapidly, and as its diameter had reached 25 mm, 
it was resected and replaced with a surgical prosthesis 12 months after the primary insult. The 
right vertebral artery, which originated from the aneurysm, was transplanted to the right 
carotid artery. 
 
Figure 8. Dissection of the whole aorta in patient 1 (a). Volume rendering technique reconstruction 
of the CT of the thoracic aorta in patient 1 showing marked dilatation of the aortic root (b). Axial CT 
image approximately at the same level as that in 1a but acquired 2 months after the first insult. 
Image shows rapid dilatation of the aortic arch and descending aorta in patient 1 (c). Aneurysm of 
the right subclavian artery in patient 1 (12 months after the primary operation) (d). 
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Figure 9. Vascular reconstructions of the aortic arch of patient 1 (a). Angiography of patient 1 after 
the stent grafting of the aortic arch (b). 
 
The thoraco-abdominal aorta, however, continued to dilate, and after it had reached a 
diameter of 54 mm, a new operation was scheduled for 14 months after the primary insult. In 
this procedure, a Y-prosthesis was first implanted into the abdominal aorta, and the legs were 
implanted upon the common iliac arteries. The superior mesenteric artery, coeliac trunk and 
both renal arteries were bypassed with separate prostheses from the main body of the Y-
prosthesis. The operation was then completed by introducing an endovascular stent graft 
between the previously implanted thoracic endoprosthesis and newly implanted bifurcated 
graft (Figure 10). The operation was complicated by a retroperitoneal hematoma, but this later 
resolved spontaneously. Three months later, CTA demonstrated a pseudoaneurysm in the 
anastomosis between the left leg of the Y-prosthesis and the common iliac artery. It was treated 
by extension of the stent graft and coil embolization of the left internal iliac artery. The patient 
has been able to return to a normal life, and the total follow-up was 3 years and 2 months 
without any additional vascular complication. 
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Figure 10: Vascular reconstructions after the last operation of patient 1. 
 
5.4.1 Marfan syndrome 
Patient 2 was a 25-year-old woman with previously diagnosed MFS. She had a Stanford type A, 
DeBakey type I dissection of the whole aorta, which was treated with a composite graft at the 
first stage. Rapid dilatation of the distal aortic arch necessitated an urgent open reconstruction 
of the arch and proximal part of the descending aorta 1 week after the primary procedure. After 
this operation, the patient had a chylous leak into the thoracic cavity, which resolved with 
drainage. 
Eventually, 4 years later, progressive dilatation of the thoraco-abdominal aorta led to 
replacement of the whole aorta and re-implantation of the visceral arteries into the aortic 
prosthesis. At the first stage, stent grafts were implanted from the femoral artery so that the 
proximal end took up a position inside the previously implanted prosthesis in the aortic arch. 
The distal end of the stent grafts reached the level of the celiac trunk. At the second stage, the 
thoraco-abdominal aorta was replaced with a combination of tubular and bifurcated prostheses. 
33 
 
 
The proximal end of the prosthesis was sutured directly to the endograft with a tapered aortic 
wall and circumferential felt reinforcement (Figure 11). Postoperatively, the patient had a 
hematoma in the left thoracic cavity, which was evacuated surgically. The patient made a full 
recovery and has returned to an active, independent lifestyle. The duration of the follow-up to 
date is 7 years, 9 months. 
 
Figure 11. Vascular reconstructions of patient 2. 
 
Patient 3 was a 22-year-old man with previously diagnosed MFS. He had an emergency 
operation for a Stanford type A, DeBakey type I AoD with a composite graft implanted. First 
years after the initial insult went uneventfully, but 14 years after the primary insult the aortic 
arch and descending aorta were dilated up to 60 mm and required a further operation. The 
supra-aortic vessels were bypassed from the previously implanted surgical prosthesis with a Y-
prosthesis, and both the arch and the descending aorta were then stent grafted from the 
composite graft. At the follow-up, a type I endoleak emerged, and it was treated with an 
additional stent graft procedure at the proximal end of the previously implanted stent graft at 
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11 months after the first stent graft operation. At present, 17 years after the primary insult, the 
patient has returned to an independent daily life, and the aneurysm is shrinking (most recent 
diameter, 45 mm). 
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6 Discussion 
 
6.1 ROLE OF INTRAOPERATIVE FENESTRATION OF AORTIC STENT GRAFTS 
 
An intraoperative percutaneous technique for fenestration of stent grafts would overcome 
problems associated with customized stent grafts. This technique may increase the availability 
of endovascular aortic repair to more patients because of its potential to decrease costs and 
waiting times. It would also offer a bailout option if important side branches are inadvertently 
occluded. 
In the experimental in vitro study, a hole created with a needle could be enlarged up to 10 
mm with sequential standard coronary and peripheral PTA balloon dilation in all grafts except 
one. The fabric of the Zenith graft was very resilient, and some residual stenosis remained after 
all dilations using various balloon sizes and even at very high pressure. Other fabrics 
responded more favorably, although they also needed quite high pressures (~20 atm). 
The cutting balloon proved to be very useful for facilitating a fully open fenestration in all 
five grafts while using a dilation pressure of 10 atm or less. The cutting balloon also seemed to 
be valuable for reducing unnecessary steps during fenestration and reducing the warm 
ischemia time of the end organ. 
Long-term effects from fabric tearing are worrisome. A potential hazard is that the tear 
would eventually enlarge and lead to an endoleak. The hole in the Gore TAG graft was round 
with smooth edges, which theoretically could be more resistant to wear and tear. In other 
fabrics, dilation with the standard PTA balloon and cutting balloon resulted in fringed edges. 
The fabrics of Endurant, Talent, Valiant, and Zenith consist of thin fibers of polyester woven 
together. As the fenestration is punctured and enlarged, the fibers break, leading to fraying of 
the edges of the fenestration. The fabric of Gore TAG is a multi-film layer of expanded 
polytetrafluoroethylene, which seems to respond to dilation mainly by stretching. 
The experiment also showed that the hole should not be created close to the metallic struts of 
the stent graft. The hole cannot be reliably sealed if a stent strut overlaps the fenestration, which 
increases the risk of endoleak. Good apposition of the side branch stent graft to the main 
prosthesis was registered in visual assessment when the fenestration was not obscured by the 
metallic network. More conclusive evidence for excluding the leakage between the fenestration 
and side branch stent graft would be obtained, however, only from a pressurized flow model 
with circulating blood. 
In situ fenestration with a re-entry catheter and steerable sheath seems technically feasible, 
though some refinements have to be made. The warm ischemia time was too long in our 
experiments, and definite renal infarction was found at autopsy. Because the animals were 
euthanized immediately after the procedure, possible renal failure could not be monitored. 
Results from clinical human studies indicate that kidney damage occurs when warm ischemia is 
longer than 30 min and that the damage is only partially reversible (49). In a test conducted by 
Riga et al. (50) in which the investigators performed antegrade fenestration into the renal arteries 
of a pig model with the help of a robot arm (the Sensei system), the total operation time was 45 
min, which is also too long for warm ischemia of the kidneys. Tse et al. (51) tested both the 
Pioneer catheter and Brockenbrough needle in the same setting in a canine model. The 
Brockenbrough needle performed better, but the ischemia time reached 60 min. Notably, these 
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experiments were conducted with healthy, young animals, in which the anatomy is very 
straightforward. In real-life patients, the anatomy is usually more challenging, leading to 
catheterization difficulties. 
The technical failure of the Outback device that we encountered in one of our experiments is 
worrisome and could lead to unnecessary delays, prolonging the already long ischemia time. 
Notably, that Outback device is not indicated for traversing graft fabrics. 
The fabric of the Endurant stent graft was also very resilient and made it difficult to advance 
the relatively low-profile 3-mm PTCA balloon through the hole created with the needle. In vitro 
testing has also indicated that enlarging the hole in the Endurant graft requires high pressure, 
up to 24–26 atm. The cutting balloon facilitates more effective dilatation of the fabric than the 
conventional balloon, but traversing the prosthesis with this large-profile device necessitates 
previous dilatation with a low-profile PTCA balloon. 
In the first pig, our guide wire was too slack and did not give enough support for the initial 
balloon to traverse the fabric. Unfortunately, we did not have stiffer guide wires available in the 
stock of our animal laboratory. Based on this experience, we were better equipped for the 
second experiment, and with a stiffer guide wire in combination with a very low-profile 
balloon, we were able to dilate the fenestration and stent it. 
We used both bare metal stents and stent grafts in our experiments. In pre-fabricated 
fenestrated stent grafts, bare metal stents were used at the beginning to secure the fenestrations. 
We sought to achieve better sealing of the fenestration, which is usually necessary when 
fenestration is done to produce an adequate proximal neck for the aortic stent graft. Stent graft 
systems are often quite stiff, and their crossing profile is considerably higher than that of bare 
metal stents. Therefore, it may not be possible to place a stent graft in the fenestration in some 
situations, for example when renal arteries are accidentally covered by an aortic stent graft. In 
those cases, the distance between the fenestration and the aneurysm is usually sufficient, and 
there should be no risk for type III endoleak even if bare stents are used. 
Based on our experiments, the different fabrics respond differently to puncture and balloon 
dilatation, and it would be worthwhile to test different kinds of stent grafts under in vivo 
conditions. 
 
6.2 TREATMENT AND FOLLOW-UP OF ANEURYSMS OF THE DESCENDING 
AORTA 
 
The experience of three Finnish university hospitals in the use of thoracic endovascular aortic 
repair (TEVAR) in the DTA encompassed a 13-year period during which stent graft technology 
and principles of treatment significantly changed. Furthermore, it also included the learning 
curve in each center, so this study provides a ‘‘real-life’’ scenario of an evolving endovascular 
therapy. 
Thirty-day postoperative mortality after urgent endovascular repair was significant (47%) 
but similar to previous reports. In the case series reported by Geisbüsch et al. (52), for example, 
the in-hospital mortality was 48% among 23 patients. Analyses of larger populations have 
shown somewhat lower in-hospital mortality: 28.4% for 299 Medicare patients (21) and 23.4% 
among 364 patients from the US Nationwide Inpatient Sample (NIS) (22). In a recent meta-
analysis, pooled 30-day mortality was 19% (53). 
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Our results are biased by the small sample size in the urgent patient group. Furthermore, 
unlike many other studies, we analyzed our data by the intention-to-treat approach, including 
those patients for whom the treatment was attempted but a stent graft was never deployed. Of 
note, we encountered two early ruptures among patients with apparently successful 
interventions primarily. Initial follow-up CTA had not been performed on either of these 
patients, which suggests that intraprocedural digital subtraction imaging is not absolutely 
reliable, especially in acute patients. This observation emphasizes the importance of early CTA 
verification that any rupture is securely excluded. Two postoperative ruptures were 
encountered among patients with access failure, which demonstrates one of the many clinical 
challenges in decision-making that needs to be considered when dealing with acute thoracic 
aortic syndromes. 
Elective repair was performed with low immediate postoperative mortality (3.7%), which is 
similar to that of previous studies (21). In the 2732-patient study by Goodney et al. (21), the in-
hospital/30-day mortality was 6.1% whereas it was 2.3% in the US NIS database (22). Stroke rate 
in our series was 4.3%, which is somewhat higher than in previous studies (22). All strokes 
occurred in patients with prior supra-aortic vessel debranching. These strokes were probably 
due to plaque embolization from the ascending aorta and not connected to the surgical 
procedure done beforehand. 
During the study period, some emerging reports indicated that routine preoperative LSA 
revascularization may be beneficial, with reduced risks of stroke, paraplegia, and arm ischemia, 
leading to the recommendation that the LSA should be routinely revascularized, especially in 
elective patients (54). This observation was also reflected in our routines, and after 2007, all 
patients who were to have their LSA covered had preliminary revascularization. This issue 
remains controversial, however (55).  
Although the volume of degenerative TAAs during the 13-year period was relatively low in 
our study (only 5.8 patients/y on average and a mean 2 patients/y/center), the outcome is still 
comparable to other registry data. This finding probably indicates that the overall volume of 
thoracic aortic interventions (158 patients, 13.2/y) is nevertheless sufficient to efficiently perform 
these procedures with acceptable complication rates. 
Access failure or difficulty in access resulted in three treatment failures. In 2 patients, the 
implantation of the prosthesis could not be completed because of narrow iliac arteries, while in 
one case, an iliac artery ruptured during deployment. This, together with the fact that 
atheromatous plaques in the ascending aorta lead to an increased risk of plaque embolization, 
emphasizes the importance of optimal preoperative evaluation of the status of the aorta and its 
branches at preoperative CTA. 
Material weakness, the potential for stent graft migration, and type I or III endoleaks during 
follow-up make regular monitoring by CTA or MRA mandatory. Two of four late ruptures 
were likely related to inadequate follow-up. Stent graft treatment has an inherent risk of type I 
or III endoleak development and the potential for late aneurysm rupture (56,57), both of which 
were seen in this study. Type I or III endoleaks were successfully treated with additional stent 
grafting or embolization without any conversion to open repair, as others have observed (56,58). 
Clearly, lifelong serial imaging is mandatory for every TEVAR patient. 
When comparing these results with open surgery, one has to bear in mind that endovascular 
treatment is still an evolving technique and that new refinements to the technique are 
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developed continuously. The importance of an adequate landing zone has become evident, and 
a length of proximal and distal neck of >15 mm has been widely accepted. Debranching of the 
aortic arch vessels greatly facilitates the endovascular treatment and permits much better 
results because an adequate landing zone is easier to achieve, for example when the LSA can be 
covered without fear of neurological complications. Introduction of rapid pacing during 
deployment of the stent graft makes precise positioning of the prosthesis much easier and more 
accurate (59). Deployment systems of the stent grafts have also evolved considerably during the 
last decade, and deployment of the stent graft has become faster, easier, and more accurate. 
Conformability of the stent graft in the aortic arch has also improved markedly and is a 
significant factor in the long-term prognosis because it reduces the risk of stent collapse in the 
inner curve of the aortic arch. Lower-profile deployment systems facilitate treatment and make 
it easier and more available for a larger patient population (59). Therefore, it is highly probable 
that the results with the endovascular technique have significantly improved since its 
introduction, and they continue to improve further. 
 
6.3 TREATMENT OF AORTIC PATHOLOGY IN CONNECTIVE TISSUE 
DISORDERS 
 
6.3.1 Marfan syndrome 
MFS causes aortic root dilatation and aneurysm formation, which eventually lead to AoD. 
Without treatment, the prognosis of the disease is poor. In the early 1970s, the mean life 
expectancy for these patients was 32±16 years, and the median (50%) cumulative probability of 
survival was only 48 years (5). The life expectancy has since, however, increased by more than 
25% and was 41±18 years in 1993 with a median (50%) cumulative probability of survival of 72 
years (5). This increase may be partly explained by the overall improvement in life expectancy 
but may also be due to the benefits of modern cardiovascular surgery. Also, perhaps a greater 
proportion of milder cases are now being identified thanks to increased recognition and 
diagnosis since the advent of molecular medicine. 
  
6.3.2 Loeys–Dietz syndrome 
LDS was first described in 2005 (6). It is a rare, autosomal dominant disorder characterized by 
hypertelorism, bifid uvula of the cleft palate, arterial tortuosity, aneurysmal disease, and AoD 
at a young age. The disease is caused by heterozygous mutations in genes encoding the TGF-β 
type 1 or 2 receptors. LDS syndrome has some overlap in clinical presentation with MFS, 
although LDS patients do not have significant long bone overgrowth or eye lens dislocation. 
Aneurysm development is, however, typically more aggressive than that seen in MFS, and 
dissection or rupture tends to occur at younger ages and at smaller aortic diameters. Life 
expectancy is reported to be as low as 26.0 years (range 0.5 to 47.0) (7). There seem to be some 
clinical differences between the two types of TGF-β receptor mutations, and those carrying 
mutations in the TGF-β type 1 receptor may be more likely to die at a younger age (60).  
The diagnosis is based on the typical clinical characteristics, family history, and molecular 
genetic testing for mutations in the TGF-β type 1 or type 2 receptor genes.  
 
39 
 
 
6.3.3 Treatment 
Patients with MFS and especially LDS are prone to developing vascular complications such as 
AoD and rupture. β-blocker therapy and AT1 antagonists may be of benefit to these patients (61), 
but their role remains under investigation (62). Replacement of the aortic root either with or 
without aortic valve replacement has been adopted as a standard therapy for the lesions in the 
ascending aorta, which has increased the life expectancy of MFS patients markedly. However, 
because of the progressive nature of these diseases, aortic dilatation tends to continue, which 
may lead to aneurysm formation, dissection, and eventually rupture in other sections of the 
aorta. Lifelong surveillance is essential, and these patients tend to require additional operations 
(63). Preventive surgical reconstruction remains controversial, however (61). 
Surgery on the DTA is challenging and requires good surgical expertise. Still, there is a 
significant risk of complications such as stroke, paraplegia or paraparesis, postoperative 
hematomas, and even death (64). Higher complication rates have been reported by low-volume 
centers with fewer than 4 cases/year, where in-hospital postoperative mortality can be as high 
as 27%, compared to the 15% recorded in some high-volume centers (20). 
Endovascular treatment is a tempting alternative for surgical treatment because patients tend 
to survive longer and have fewer complications at least in the short term (16,24). However, in 
connective tissue disorders such as MFS and LDS, the aortic wall is very prone to further 
dissection and aortic dilatation. The current recommendation is that endovascular treatment 
should be reserved as a bailout procedure or as a procedure following prior aortic repair, where 
both landing zones lie within previously sited prosthetic grafts (65). 
The present study clearly demonstrates the progressive nature of these diseases and 
especially LDS. This progression necessitates aggressive treatment and vigorous follow-up. 
Unfortunately, the diagnosis is not always clear when the patient becomes symptomatic, as 
happened with patient 1. The correct diagnosis was suspected only 2.5 months after the first 
incident, and the final results of genetic testing were received 11 months after the dissection of 
the ascending aorta. Luckily, this delay did not lead to any further complications, and corrective 
surgery for the entire aorta and supra-aortic vessels could be performed. Despite corrective 
surgery, these connective tissue disorders may still lead to new complications, as was the case 
for all of our patients. Therefore, patients need to be monitored for the rest of their lives with 
CTA or MRA. The patient cases also demonstrate that if the landing zone of the endograft lies 
within native, untreated aorta, these patients are prone to developing complications such as 
further dilatation of the aorta. As the aorta continues to dilate at the level of the landing zone, it 
eventually leads to type I endoleak and further dilatation and possibly to the rupture of the 
treated aneurysm. 
On the other hand, our experiences demonstrate that complications of the connective tissue 
disorders can be treated effectively utilizing surgical and endovascular techniques in 
combination. Patient 2 has survived almost 8 years after the first insult and after the last 
operation, there have been no signs of further vascular complications and she has even 
delivered a healthy baby. Patient 3 is living active life and there haven’t also been any signs of 
further complications and the aneurysm is shrinking. The patient has survived up to 17 years, 
which is quite remarkable, considering the devastating nature of the disease and the natural 
course, if left untreated. 
40 
 
 
41 
 
 
7 Conclusions 
 
I and II: Intraoperative fenestration of stent grafts can be done, but the surgeon must be familiar 
with the fact that stent graft materials respond differently to dilatation. Use of high pressure 
balloons is mandatory, and a cutting balloon aids considerably in the dilatation. The technique 
can also be used in vivo, but a steerable sheet and Outback device resulted in a too-long 
ischemia time for the kidneys, and we cannot recommend this technique for elective situations. 
However, in acute situations and as a bailout procedure, it can be useful. 
 
III: Endovascular treatment of TAA is relatively safe, at least in the elective setting. However, to 
reduce the risk of periprocedural and postoperative complications, multidisciplinary and 
detailed preoperative imaging-based planning is helpful. A rigorous postoperative surveillance 
program is compulsory for early detection and prompt treatment of late type I or III endoleak 
and to reduce the risk of late ruptures. 
 
IV: Marfan syndrome and especially Loeys–Dietz syndrome are debilitating connective tissue 
disorders, and such patients are very prone to developing vascular complications, particularly 
of the aorta. The nature of these diseases mandates aggressive treatment strategies and close 
surveillance programs. Open surgery remains the mainstay of the treatment, but endovascular 
options should be considered whenever possible to reduce operative complications. 
Endovascular treatment should be planned so that the landing zones lie within the previously 
treated aorta. 
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Open surgery of thoracic aorta is as-
sociated with relatively high mortality 
and morbidity. Stent graft treatment 
was introduced on the side of open 
surgery to reduce mortality and mor-
bidity associated with the treatment. 
Stent graft treatment has, however, 
some limitations, but intra-operative 
fenestration may be a way to make 
this treatment more available. This 
study also confirmed that endovascu-
lar treatment of a thoracic aortic aneu-
rysm is relatively safe, but a rigorous 
postoperative surveillance program is 
still compulsory. In connective tis-
sue disorders open surgery is still the 
mainstay of the treatment, but endo-
vascular option should be considered 
to reduce operative complications.
